The MMP1 (-16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome

AIDS

Volumn 24, Issue 16, 2010, Pages 2499-2506

  Montes, Angel H ^a   Valle Garay, Eulalia ^a   Suarez Zarracina, Tomas ^b   Melon, Santiago ^b   Martinez, Esteban ^c   Carton, Jose A ^b   Collazos, Julio ^d   Asensi, Víctor ^b  

^a Department of Biochemistry and Molecular Biology ^*  (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Dantiretrovirals; HIV; Lipodystrophy; Matrix metalloproteinases; Polymorphism

Indexed keywords

ATAZANAVIR; COLLAGENASE 3; EFAVIRENZ; FOSAMPRENAVIR; GELATINASE A; GELATINASE B; INDINAVIR; INTERSTITIAL COLLAGENASE; LOPINAVIR; NELFINAVIR; NEUTROPHIL COLLAGENASE; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; STROMELYSIN; STROMELYSIN 2; TIPRANAVIR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OUTPATIENT DEPARTMENT; PATHOGENESIS; PRIORITY JOURNAL; RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ABSORPTIOMETRY, PHOTON; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SPAIN;

EID: 78549283756     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833e922c     Document Type: Article

References (43)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
2. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-598.
3. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003;17:S141-S148.
4. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005;39:395-400.
5. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62. (Pubitemid 40075680)
6. Asensi V, Martin-Roces E, Carton JA, Collazos J, Maradona JA, Alonso A, et al. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2004;39:240-247.
7. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-F32.
8. Brinkman K, Smeitink jA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral- therapy-related lipodystrophy. Lancet 1999;354:1112-1115.
9. Cherry C, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesseling SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002;30:271-277.
10. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, etal. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001;15:1801-1809.
11. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-1338.
12. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-protease inhibitors to nevirapine. AIDS 1999;13:805-810.
13. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002;288:207-215.
14. Haubrich RH, RiddlerSA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor- sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-1119.
15. Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggini V, Lepri AC, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008; 22:1769-1778.
16. Ranade K, Geese WJ, Noor M, Flint O, Tebas P, Mulligan K, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 2008; 22:1561-1568.
17. Asensi V, Rego C, Montes AH, Collazos J, Carton JA, Castro MG, et al. IL-1b (+3954 C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. Genet Med 2008;10:215-223.
18. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNFα promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002; 16:2013-2018.
19. Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, et al. Tumour necrosis factor-alpha gene -238 G/A promoter polymorphism associated with a more rapid onset of lipody- strophy. AIDS 2003;17:121-123.
20. Tarr PE, Telenti A. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir Ther 2007;12:999-1013.
21. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4:617-629.
22. Johnson J, Albu JB, Engelson ES, Fried SK, Inada Y, Ionescu G, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286:261-271.
23. Elkington PT, O?Kane CM, FriedlandJ S. The paradox of matrix metalloproteinases in infectious diseases. Clin Exp Immunol 2005;142:12-20.
24. RutterJL, Mitchell TI, Butticè G, Meyers J, Gusella JF, Ozelius LJ, et al. A single nucleotide polymorphism in the matrix metallo- proteinase-1 creates an Ets binding site and augments transcription. Cancer Res 1998; 58:5321-5325.
25. Tower GB, Coon CI, Belguise K, Chalbos D, Brinckerhoff CE. Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP1 promoter. Eur J Biochem 2003; 270:4216-4225.
26. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/ deletion polymorphism in its promoter region. Cancer Res 1999;59:4225-4227.
27. Montes AH, Valle-Garay E, Alvarez V, Pevida M, Perez EG, Paz J, et al. A functional polymorphism in MMP1 could influence osteomyelitis development. J Bone Miner Res 2010; 25:921-925.
28. Latronico T, Liuzzi GM, Riccio P, Lichtner M, Mengoni F, D'Agostino C, et al. Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV- infected patients. AIDS 2007; 21:677-684.
29. Bourlier V, Zakaroff-Girard A, De Barros S, Pizzacalla C, de Saint Front VD, Lafontan M, et al. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J Pharmacol Exp Ther 2005;312:1272-1279.
30. De Barros S, Zakaroff-Girard A, Lafontan M, Galitzky J, Bourlier V. Inhibition of human preadipocyte proteosomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9. J Pharmacol Exp Ther 2007; 320:291-299.
31. Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, Young SG, et al. HIV protease inhibitors block the zinc me- talloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A 2007; 104: 13432-13437.
32. Hudon SE, Coffinier C, Michaelis S, Fong LG, Young SG, Hrycyna CA. HIV-protease inhibitors block the enzymatic activity of purified Ste24p. Biochem Biophys Res Commun 2008; 374:365-368.
33. Coffinier C, Hudon SE, Lee R, Farber EA, Nobumori C, Miner JH, et al. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl- prealamin A in cells. J Biol Chem 2008;283:9797-9804.
34. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Tanus-Santos JE. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretro- viral therapy in HIV patients. Pharmacogenom J 2009; 9:265-273.
35. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389-1398.
36. Asensi V, Martin-Roces E, Collazos J, Cartón JA, Maradona JA, Alonso A, et al. Association between physical and echographic fat thickness assessments and a lipodystrophy grading scale in lypodystrophic HIV patients. Practical implications. AIDS Res Human Retroviruses 2006; 22:830-836.
37. Bouloumie A, Sengenès C, Portolan G, Galitzky J, Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 2001; 50:2080-2086.
38. Iwata T, Kuwajima M, Sukeno A, Ishimaru N, Hayashi Y, Wabitsch M, et al. YKL-40 secreted from adipose tissue inhibits degradation of type I collagen. Biochem Biophys Res Commun 2009;388:511-516.
39. Nho YK, Ha E, Yu KI, ChungJ, Wook NC, Chung IS, et al. Matrix metalloproteinase-1 promoter is associated with body mass index in Korean population with aged or equal to 50 years. Clin Chim Acta 2008;396:14-17.
40. Diaz-Delfin J, Gallego-Escuredo JM, Milanski M, Domigo JC, Gutierrez MM, Mateo MG, et al. Comparison of the effects of lopinavir/ritonavir and efavirenz on gene expression and differentiation of human adipocytes. [abstract P-01]. In: 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. London, UK 2008. Antiviral Ther 2008;13(Suppl 4):A23.
41. Duong M, Petit F M, Piroth L, Grappin M, Buisson M, Chavanet P, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Deflc Syndr 2001;27:245-250.
42. Collazos J, Rodriguez-Guardado A, Maradona JA, Mayo J, Asensi V, Ibarra S, et al. Factors influencing the development of lipodystrophy in human immunodeficiency virus-infected patients. Scand J Infect Dis 2003; 35:339-340.
43. Tien PC, Bacchetti P, Gripshover B, Overton ET, Rimland D, Kotler D, et al. Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women. J Acquir Immune Defic Syndr 2007;45:60-65.